Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study.

2.50
Hdl Handle:
http://hdl.handle.net/2336/87616
Title:
Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study.
Authors:
Torsdottir, Gudlaug; Gudmundsson, Gretar; Kristinsson, Jakob; Snaedal, Jon; Johannesson, Torkell
Citation:
Neuropsychiatr Dis Treat. 2009, 5(1):55-9
Issue Date:
2009
Abstract:
At the time of this study, there were five known patients with Wilson disease (WD) in Iceland. The mutation, a 7-bp deletion in exon 7 on chromosome 13 for WD, is only known in Iceland. In twenty healthy Icelandic heterozygotes for WD and their age- and gender-matched controls, copper concentration in plasma, ceruloplasmin (CP) concentration, CP oxidative activity and CP-specific oxidative activity in serum and superoxide dismutase (SOD1) activity in erythrocytes were determined. The same determinations were done on the five WD patients. There was no significant difference in these parameters between the heterozygotes and the controls, although an inclination toward lower CP determinations and higher SOD1 activity in the heterozygotes was noted. As expected the WD patients were low on the copper and CP parameters, but their SOD1 activity was within the upper normal range. In conclusion, the CP parameters and SOD1 activity are within the normal range in Icelandic heterozygotes for WD, although with a trend toward mild dyshomeostasis. This may indicate subclinical copper retention in the heterozygotes, but a bigger study group is needed to confirm this.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.dovepress.com/ceruloplasmin-and-superoxide-dismutase-sod1-in-heterozygotes-for-wilso-peer-reviewed-article-NDT

Full metadata record

DC FieldValue Language
dc.contributor.authorTorsdottir, Gudlaugen
dc.contributor.authorGudmundsson, Gretaren
dc.contributor.authorKristinsson, Jakoben
dc.contributor.authorSnaedal, Jonen
dc.contributor.authorJohannesson, Torkellen
dc.date.accessioned2009-12-08T15:46:05Z-
dc.date.available2009-12-08T15:46:05Z-
dc.date.issued2009-
dc.date.submitted2009-12-08-
dc.identifier.citationNeuropsychiatr Dis Treat. 2009, 5(1):55-9en
dc.identifier.issn1176-6328-
dc.identifier.pmid19557100-
dc.identifier.urihttp://hdl.handle.net/2336/87616-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractAt the time of this study, there were five known patients with Wilson disease (WD) in Iceland. The mutation, a 7-bp deletion in exon 7 on chromosome 13 for WD, is only known in Iceland. In twenty healthy Icelandic heterozygotes for WD and their age- and gender-matched controls, copper concentration in plasma, ceruloplasmin (CP) concentration, CP oxidative activity and CP-specific oxidative activity in serum and superoxide dismutase (SOD1) activity in erythrocytes were determined. The same determinations were done on the five WD patients. There was no significant difference in these parameters between the heterozygotes and the controls, although an inclination toward lower CP determinations and higher SOD1 activity in the heterozygotes was noted. As expected the WD patients were low on the copper and CP parameters, but their SOD1 activity was within the upper normal range. In conclusion, the CP parameters and SOD1 activity are within the normal range in Icelandic heterozygotes for WD, although with a trend toward mild dyshomeostasis. This may indicate subclinical copper retention in the heterozygotes, but a bigger study group is needed to confirm this.en
dc.language.isoenen
dc.publisherDove Medical Pressen
dc.relation.urlhttp://www.dovepress.com/ceruloplasmin-and-superoxide-dismutase-sod1-in-heterozygotes-for-wilso-peer-reviewed-article-NDTen
dc.subject.meshWilson Diseaseen
dc.subject.meshCeruloplasminen
dc.subject.meshIcelanden
dc.titleCeruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study.en
dc.typeArticleen
dc.contributor.departmentInstitute of Pharmacy, Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Iceland, Reykjavík, Iceland;en
dc.identifier.journalNeuropsychiatric disease and treatmenten

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.